166 related articles for article (PubMed ID: 11422011)
1. Stopping rules for phase II studies.
Stallard N; Whitehead J; Todd S; Whitehead A
Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
[TBL] [Abstract][Full Text] [Related]
2. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
3. A predictive probability design for phase II cancer clinical trials.
Lee JJ; Liu DD
Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
[TBL] [Abstract][Full Text] [Related]
4. Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.
Goffin JR; Pond GR
BMC Med Res Methodol; 2011 Dec; 11():164. PubMed ID: 22151297
[TBL] [Abstract][Full Text] [Related]
5. Bayesian monitoring of phase II trials in cancer chemoprevention.
Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the data combination rule for seamless phase II/III clinical trials.
Hampson LV; Jennison C
Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
[TBL] [Abstract][Full Text] [Related]
7. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
Fazzari M; Heller G; Scher HI
Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
[TBL] [Abstract][Full Text] [Related]
8. Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials.
Song G; Ivanova A
J Biopharm Stat; 2015; 25(6):1206-14. PubMed ID: 26383917
[TBL] [Abstract][Full Text] [Related]
9. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
10. Designing a series of decision-theoretic phase II trials in a small population.
Hee SW; Stallard N
Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
[TBL] [Abstract][Full Text] [Related]
11. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
12. Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma.
Dutton P; Love SB; Billingham L; Hassan AB
Stat Methods Med Res; 2018 May; 27(5):1451-1463. PubMed ID: 27587590
[TBL] [Abstract][Full Text] [Related]
13. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
Zohar S; Chevret S
Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
[TBL] [Abstract][Full Text] [Related]
14. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
15. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
16. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
17. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
18. Comparing Bayesian early stopping boundaries for phase II clinical trials.
Jiang L; Yan F; Thall PF; Huang X
Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
[TBL] [Abstract][Full Text] [Related]
19. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
20. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]